This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
The costing was undertaken retrospectively on the same patient sample as that used in the effectiveness study.
Study sample
The sample size was calculated in the planning phase of the study to assure a power of 80%. After accounting for stratification by centre and surgical procedure and an anticipated 5% withdrawal rate, 78 patients per group were required. According to the authors' summary of the trial profile (which was slightly unclear), there were 653 potential participants in the clinic. Eighty-three patients were missed, 342 were ineligible and 55 refused to participate. Of the 179 patients who consented, 12 were cancelled by anaesthesia, 2 were cancelled by surgery and 5 withdrew consent. One hundred and fifty-nine patients were randomised during the study, but three subsequently withdrew: one patient had clinical signs strongly predictive of a difficult intubation, which was missed during the preoperative assessment clinic visit but detected prior to induction, one patient had severe nausea prior to induction, and one patient did not undergo the scheduled procedure. In total, 156 patients completed the study. Upon entry into the operating room, 77 patients were allocated to the sevoflurane group and 79 to the propofol group.
Study design
The study was a randomised controlled trial. A random numbers table was used to allocate the patients to the two groups. The duration of follow-up was the first 24 hours after surgery. There was no loss to follow-up. The anaesthesiologists and operating room nurses were not blinded to the induction technique used, but the patients themselves were not informed of the induction technique that they received. The surgical team was blinded to the induction technique. The postoperative data collectors and the data analysts were blinded to the intervention.
Analysis of effectiveness
The analysis was conducted on the basis of treatment completers only, as 3 patients withdrew post-randomisation. These individuals were not considered at analysis. The primary health outcome was the frequency of moderate to severe PONV over the first 24 hours after surgery. Severity of PONV was measured using a 10-cm visual analogue scale (VAS), with scores greater than 3 considered being moderate to severe. The secondary outcomes included: moderate to severe pain over the first 24 hours after surgery (measured using a 10-cm VAS), ease of intubation (measured using a six-item 12-point score), anaesthetic induction and emergence times, the time required to achieve fast-track criteria, and the amount of postoperative anti-emetics and analgesics used.
There were no statistically significant differences in the physical characteristics or the distribution of PONV risk factors between the two groups.
Effectiveness results
There was no statistically significant difference in the frequency of moderate to severe PONV over 24 hours between the sevoflurane group (53.2%) and the propofol group (36.7%).
An odds ratio, adjusted for the number of PONV risk factors, of 1.79 (95% confidence interval, CI: 0.92 -3.38; p=0.12) was reported.
No differences were seen between the two groups in their frequencies of postoperative pain, or in their intubating conditions, induction and emergence times, and time to achieve fast-track discharge criteria.
Patients in the sevoflurane group received more morphine (11 mg versus 8 mg; p<0.001) in the post anaesthetic care unit.
